These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 22977012)

  • 41. Effect of PPAR-β/δ agonist GW0742 treatment in the acute phase response and blood-brain barrier permeability following brain injury.
    Chehaibi K; le Maire L; Bradoni S; Escola JC; Blanco-Vaca F; Slimane MN
    Transl Res; 2017 Apr; 182():27-48. PubMed ID: 27818230
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Peroxisome proliferator-activated receptor β/δ agonist GW0742 ameliorates cerulein- and taurocholate-induced acute pancreatitis in mice.
    Paterniti I; Mazzon E; Riccardi L; Galuppo M; Impellizzeri D; Esposito E; Bramanti P; Cappellani A; Cuzzocrea S
    Surgery; 2012 Jul; 152(1):90-106. PubMed ID: 22521259
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Activation of peroxisome proliferator-activated receptor-beta/delta attenuates myocardial ischemia/reperfusion injury in the rat.
    Kapoor A; Collino M; Castiglia S; Fantozzi R; Thiemermann C
    Shock; 2010 Aug; 34(2):117-24. PubMed ID: 19997057
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of PPAR-β/δ/miR-17/TXNIP pathway in neuronal apoptosis after neonatal hypoxic-ischemic injury in rats.
    Gamdzyk M; Doycheva DM; Malaguit J; Enkhjargal B; Tang J; Zhang JH
    Neuropharmacology; 2018 Sep; 140():150-161. PubMed ID: 30086290
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mass spectrometry-based characterization of new drugs and methods of performance manipulation in doping control analysis.
    Thevis M; Thomas A; Kohler M; Beuck S; Möller I; Schäfer M; Rodchenkov G; Yin S; Loo JA; Geyer H; Schänzer W
    Eur J Mass Spectrom (Chichester); 2010; 16(3):301-12. PubMed ID: 20530837
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evidence for the role of peroxisome proliferator-activated receptor-beta/delta in the development of spinal cord injury.
    Paterniti I; Esposito E; Mazzon E; Galuppo M; Di Paola R; Bramanti P; Kapoor A; Thiemermann C; Cuzzocrea S
    J Pharmacol Exp Ther; 2010 May; 333(2):465-77. PubMed ID: 20176685
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of PPARδ agonist on stearoyl-CoA desaturase 1 in human pancreatic cancer cells: role of MEK/ERK1/2 pathway.
    Byagowi S; Naserpour Farivar T; Najafipour R; Sahmani M; Darabi M; Fayezi S; Mirshahvaladi S; Darabi M
    Can J Diabetes; 2015 Apr; 39(2):123-7. PubMed ID: 25575964
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Delayed activation of PPAR-β/δ improves long-term survival in mouse sepsis: effects on organ inflammation and coagulation.
    Busch D; Kapoor A; Rademann P; Hildebrand F; Bahrami S; Thiemermann C; Osuchowski MF
    Innate Immun; 2018 May; 24(4):262-273. PubMed ID: 29697010
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Peroxisome proliferator-activated receptor-delta induces insulin-induced gene-1 and suppresses hepatic lipogenesis in obese diabetic mice.
    Qin X; Xie X; Fan Y; Tian J; Guan Y; Wang X; Zhu Y; Wang N
    Hepatology; 2008 Aug; 48(2):432-41. PubMed ID: 18627005
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PPARδ activation attenuates hepatic steatosis in Ldlr-/- mice by enhanced fat oxidation, reduced lipogenesis, and improved insulin sensitivity.
    Bojic LA; Telford DE; Fullerton MD; Ford RJ; Sutherland BG; Edwards JY; Sawyez CG; Gros R; Kemp BE; Steinberg GR; Huff MW
    J Lipid Res; 2014 Jul; 55(7):1254-66. PubMed ID: 24864274
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PPAR-β/δ activation promotes phospholipid transfer protein expression.
    Chehaibi K; Cedó L; Metso J; Palomer X; Santos D; Quesada H; Naceur Slimane M; Wahli W; Julve J; Vázquez-Carrera M; Jauhiainen M; Blanco-Vaca F; Escolà-Gil JC
    Biochem Pharmacol; 2015 Mar; 94(2):101-8. PubMed ID: 25662586
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Metabolic fate of sipoglitazar, a novel oral PPAR agonist with activities for PPAR-γ, -α and -δ, in rats and monkeys and comparison with humans in vitro.
    Nishihara M; Sudo M; Kamiguchi H; Kawaguchi N; Maeshiba Y; Kiyota Y; Takahashi J; Tagawa Y; Kondo T; Asahi S
    Drug Metab Pharmacokinet; 2012; 27(2):223-31. PubMed ID: 22123126
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Peroxisome Proliferator-Activated Receptor Delta Agonist (PPAR- δ) and Selective Androgen Receptor Modulator (SARM) Abuse: Clinical, Analytical and Biological Data in a Case Involving a Poisonous Combination of GW1516 (Cardarine) and MK2866 (Ostarine).
    Kintz P; Gheddar L; Paradis C; Chinellato M; Ameline A; Raul JS; Oliva-Labadie M
    Toxics; 2021 Oct; 9(10):. PubMed ID: 34678947
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gene Doping with Peroxisome-Proliferator-Activated Receptor Beta/Delta Agonists Alters Immunity but Exercise Training Mitigates the Detection of Effects in Blood Samples.
    Sibille B; Mothe-Satney I; Le Menn G; Lepouse D; Le Garf S; Baudoin E; Murdaca J; Moratal C; Lamghari N; Chinetti G; Neels JG; Rousseau AS
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768927
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PPAR alpha, more than PPAR delta, mediates the hepatic and skeletal muscle alterations induced by the PPAR agonist GW0742.
    Faiola B; Falls JG; Peterson RA; Bordelon NR; Brodie TA; Cummings CA; Romach EH; Miller RT
    Toxicol Sci; 2008 Oct; 105(2):384-94. PubMed ID: 18593727
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Peroxisome proliferator-activated receptor beta/delta activation improves angiotensin II-induced cardiac hypertrophy in vitro.
    Sheng L; Ye P; Liu YX; Han CG; Zhang ZY
    Clin Exp Hypertens; 2008 Feb; 30(2):109-19. PubMed ID: 18293166
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recent Updates on Peroxisome Proliferator-Activated Receptor δ Agonists for the Treatment of Metabolic Syndrome.
    Grewal AS; Beniwal M; Pandita D; Sekhon BS; Lather V
    Med Chem; 2016; 12(1):3-21. PubMed ID: 26004782
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synthesis and evaluation of an orally available "Y"-shaped biaryl peroxisome proliferator-activated receptor δ agonist.
    Kim DS; Lee J; Londhe AM; Kadayat TM; Joo J; Hwang H; Kim KH; Pae AN; Chin J; Cho SJ; Kang H
    Bioorg Med Chem; 2018 Aug; 26(15):4382-4389. PubMed ID: 30054191
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Discovery of first-in-class thiazole-based dual FFA1/PPARδ agonists as potential anti-diabetic agents.
    Li Z; Chen Y; Zhou Z; Deng L; Xu Y; Hu L; Liu B; Zhang L
    Eur J Med Chem; 2019 Feb; 164():352-365. PubMed ID: 30605833
    [TBL] [Abstract][Full Text] [Related]  

  • 60. VCAM-1-targeted and PPARδ-agonist-loaded nanomicelles enhanced suppressing effects on apoptosis and migration of oxidized low-density lipoprotein-induced vascular smooth muscle cells.
    Wei G; Hao L; Li X; Xu W; Liu F; Peng Q; Lv S
    Biosci Rep; 2020 May; 40(5):. PubMed ID: 32314783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.